Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
Author:
Publisher
Frontiers Media SA
Subject
Cancer Research,Oncology
Reference78 articles.
1. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008
2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002
3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study;Zhou;Lancet Oncol,2011
4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial;Rosell;Lancet Oncol,2012
5. Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies;Sechler;Pharmacogenom Personal Med,2013
Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Anti-proliferative and Apoptotic Efficacy of Nano-PLGA encapsulated Quercetin Molecules by down-regulation of Akt in K-ras mutated NSCLC cell lines, A549 and H460;2024-03-19
2. BDH1‐mediated LRRC31 regulation dependent on histone lysine β‐hydroxybutyrylation to promote lung adenocarcinoma progression;MedComm;2023-12
3. Application of aptamer functionalized nanomaterials in targeting therapeutics of typical tumors;Frontiers in Bioengineering and Biotechnology;2023-02-16
4. Protein-Targeted Degradation Agents Based on Natural Products;Pharmaceuticals;2022-12-28
5. The EDN1/EDNRA/β‑arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation;International Journal of Oncology;2022-11-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3